Grifols S.A. (GRFS)

NASDAQ: GRFS · IEX Real-Time Price · USD
8.96
+0.06 (0.67%)
Aug 8, 2022 4:00 PM EDT - Market closed
0.67%
Market Cap 6.13B
Revenue (ttm) 5.61B
Net Income (ttm) 214.46M
Shares Out 684.19M
EPS (ttm) 0.10
PE Ratio 89.60
Forward PE 20.83
Dividend n/a
Ex-Dividend Date n/a
Volume 799,203
Open 9.24
Previous Close 8.90
Day's Range 8.94 - 9.24
52-Week Range 8.29 - 15.90
Beta 0.14
Analysts Buy
Price Target 14.74 (+64.5%)
Earnings Date Aug 4, 2022

About GRFS

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital div... [Read more...]

Industry Biotechnology
IPO Date May 17, 2006
Employees 27,584
Stock Exchange NASDAQ
Ticker Symbol GRFS
Full Company Profile

Financial Performance

In 2021, Grifols's revenue was 4.93 billion, a decrease of -7.62% compared to the previous year's 5.34 billion. Earnings were 188.73 million, a decrease of -69.49%.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for GRFS stock is "Buy." The 12-month stock price forecast is 14.74, which is an increase of 64.51% from the latest price.

Price Target
$14.74
(64.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Clas...

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint r...

5 High-Performing Stocks in Historical Low PS Model Portfolio

According to model portfolio statistics, five stocks in the Historical Low Price-Sales Model Portfolio that have gained more than 6% in the year to date are Banco de Chile ( BCH , Financial), LTC Proper...

Other symbols: BCHDOXEDULTC

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

These three healthcare stocks should hold their value for years.

Other symbols: TAK

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Disc...

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint re...

Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022

BARCELONA, Spain, April 29, 2022 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) announced that it has filed its 2021 Annual Report on Form 20-F with the United States ...

Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and i...

- After obtaining all regulatory approvals, Grifols has closed the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, which owns 90% of the ordinary shares and 1...

Grifols partners with Feeding America® to help address hunger in the U.S.

BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health...

Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithro...

BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced a collaboration with End...

Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year

BARCELONA, Spain, Feb. 9, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and provider of technologies and services for...

2 Healthcare Stocks That Could Help Make You a Fortune

Their dividends will be trickling into your account quarter after quarter.

Other symbols: BMY

New Strong Sell Stocks for January 6th

CPSI, GRFS, LE, and NESR have been added to the Zacks Rank #5 (Strong Sell) List on January 6, 2022

Other symbols: CPSILENESR

Grifols acquires its first plasma donation center in Canada

BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today announced the...

Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma

BARCELONA, Spain, Nov. 30, 2021 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in the development of plasma-derived therapies, today announced the opening of its 300th p...

Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option ...

BARCELONA, Spain, Nov. 4, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest albumin p...

Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-s...

BARCELONA, Spain, Oct. 19, 2021 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of co...

New Strong Sell Stocks for September 22nd

MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021

Other symbols: IMCCINTZMANU

Pharma deal: Biotest up 12% after Grifols to pay $1.3 billion for majority stake

Spanish pharmaceutical company Grifols SA said Friday that it has reached an agreement to acquire a majority stake in German peer Biotest AG.

Grifols Sells Off With Effects of Pandemic

Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.

Moving Average Crossover Alert: Grifols (GRFS)

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Singapore's sovereign fund invests $1 billion in Grifols's U.S. unit

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutical...

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to ...

BARCELONA, Spain, June 1, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylax...

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

The center will collect real-world data on AMBAR® clinical program - AMBAR® Center combines Grifols' more than 15 years of knowledge researching this devastating disease with the experience of the non-p...

Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the ...

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributin...

5 Profitable Stocks With a Margin of Safety

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

Other symbols: AOSCBOEICLRMPW

Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

BARCELONA, Spain, April 15, 2021   /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years...